Incyte price to book ratio INCY

Market value divided by the book value of the company's net assets, since 2016.

Today, Oct 23, 2026: 3.7×
10-year median: 5.2×
Against its 10-year history: 20th; percentile: 0 is its lowest day, 100 its highest
10-year range: 2.2× to 67.4×
Peer median: 6.1×

Incyte's price to book ratio is 3.7× as of Oct 23, 2026.

That is below its ten-year median of 5.2×, lower than on 80% of days in the last ten years.

Over that time it ranged from 2.2× in May 2024 to 67.4× in Mar 2017.

The median for 10 biotech stocks of a similar size is 6.1×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.7×	3.4×	4.6×
2025	4.2×	3.1×	4.5×
2024	4.2×	2.2×	5.1×
2023	2.9×	2.4×	4.5×
2022	4.2×	3.6×	5.3×
2021	5.1×	4.5×	9.0×
2020	8.0×	5.6×	11.9×
2019	7.9×	7.0×	9.8×
2018	7.4×	6.9×	12.2×
2017	11.4×	11.4×	67.4×
2016	51.1×	44.6×	199×

Against its peers

Companies in Biotechnology nearest Incyte's size, closest first, today.

Company	Price to book ratio
INCYIncyte	3.7×
UTHRUnited Therapeutics	3.9×
ALNYAlnylam Pharmaceuticals	22.1×
EXELExelixis	8.7×
NBIXNeurocrine Biosciences	3.9×
HALOHalozyme Therapeutics	99.3×
ONCBeOne Medicines	8.3×
TECHBIO-TECHNE	5.4×
RGENRepligen	4.7×
KRYSKrystal Biotech	6.8×
REGNRegeneron Pharmaceuticals	2.6×
Peer median	6.1×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Incyte

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.